Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is probably the most important article about Optune. It updates the data reported the prior year and shows a little better results. If you can maintain over 90% compliance, the % of patients alive at 5 years was 29.3% compared to 4.5% in the control group which was Temodar and whatever else the doctor and patient wanted to use. This is the best survival rate ever reported in a large brain tumor trial and should finally put to rest any resistance to it's use. At this point, Optune (plus Temodar) should be considered the new standard of care.
Posted on: 01/26/2019
Click HERE to return to brain tumor news headlines